Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy

Gut

Volumn 61, Issue 5, 2012, Pages 725-733

  Hector, Suzanne ^a   Rehm, Markus ^a   Schmid, Jasmin ^a   Kehoe, Joan ^a,b   McCawley, Niamh ^a,b   Dicker, Patrick ^a   Murray, Frank ^b   McNamara, Deborah ^b   Kay, Elaine W ^b   Concannon, Caoimhin G ^a   Huber, Heinrich J ^a   Prehn, Jochen H M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROCASPASE 3; PROCASPASE 3 ACTIVATOR; PROCASPASE 9; PROTEASOME INHIBITOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS ANTAGONIST;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLON; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MATHEMATICAL MODEL; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SIMULATION; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BIOLOGICAL MARKERS; CASPASES; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; FLUOROURACIL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PRINCIPAL COMPONENT ANALYSIS; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

EID: 84859620386     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300433     Document Type: Article

References (46)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. (Pubitemid 38702845)
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
3. Rehm M, Huber HJ, Dussmann H, et al. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J 2006;25:4338-49. (Pubitemid 44435231)
4. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-46. (Pubitemid 40065523)
5. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-9. (Pubitemid 30211165)
6. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89. (Pubitemid 27508237)
7. Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-4. (Pubitemid 27317977)
8. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
9. Ferreira CG, van der Valk P, Span SW, et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 2001;7:2468-74. (Pubitemid 32751651)
10. Seligson DB, Hongo F, Huerta-Yepez S, et al. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 2007;13:6056-63. (Pubitemid 350075062)
11. Xiang G, Wen X, Wang H, et al. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol 2009;100:708-12.
12. Krajewska M, Kim H, Kim C, et al. Analysis of apoptosis protein expression in earlystage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005;11:5451-61. (Pubitemid 41060821)
13. Zlobec I, Vuong T, Compton CC. The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. Cancer 2006;106:284-6. (Pubitemid 43100435)
14. Endo K, Kohnoe S, Watanabe A, et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep 2009;21:351-5.
15. Putt KS, Chen GW, Pearson JM, et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2006;2:543-50. (Pubitemid 44413237)
16. Palmerini F, Devilard E, Jarry A, et al. Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma. Hum Pathol 2001;32:461-7. (Pubitemid 32506514)
17. Huber HJ, Rehm M, Plchut M, et al. APOPTO-CELL - a simulation tool and interactive database for analyzing cellular susceptibility to apoptosis. Bioinformatics 2007;23:648-50. (Pubitemid 46522606)
18. Altman DG, Bland JM. Diagnostic tests. 1: sensitivity and specificity. BMJ 1994;308:1552.
19. O'Connor CL, Anguissola S, Huber HJ, et al. Intracellular signaling dynamics during apoptosis execution in the presence or absence of X-linked-inhibitor-of-apoptosisprotein. Biochim Biophys Acta 2008;1783:1903-13.
20. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15.
21. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-57. (Pubitemid 351469448)
22. Wolan DW, Zorn JA, Gray DC, et al. Small-molecule activators of a proenzyme. Science 2009;326:853-8.
23. Murphy BM, O'Neill AJ, Adrain C, et al. The apoptosome pathway to caspase activation in primary human neutrophils exhibits dramatically reduced requirements for cytochrome C. J Exp Med 2003;197:625-32. (Pubitemid 36314657)
24. Hill MM, Adrain C, Duriez PJ, et al. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J 2004; 23:2134-45. (Pubitemid 38737740)
25. Rehm M, Dussmann H, Prehn JH. Real-time single cell analysis of Smac/DIABLO release during apoptosis. J Cell Biol 2003;162:1031-43. (Pubitemid 37174186)
26. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006;131:729-37. (Pubitemid 44307064)
27. Sjo OH, Lunde OC, Nygaard K, et al. Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis 2008;10:33-40. (Pubitemid 350238561)
28. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
29. Hector S, Prehn JH. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 2009;1795:117-29.
30. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-16.
31. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
32. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11. (Pubitemid 32144287)
33. Hanigan CL, Van Engeland M, De Bruine AP, et al. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 2008;135:1654-64.e2.
34. Lichtinghagen R, Musholt PB, Lein M, et al. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 2002;42:398-406. (Pubitemid 35175803)
35. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304-13.
36. Holcik M, Sonenberg N, Korneluk RG. Internal ribosome initiation of translation and the control of cell death. Trends Genet 2000;16:469-73.
37. Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006;20:515-24. (Pubitemid 43345317)
38. Paik SS, Jang KS, Song YS, et al. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol 2007;14:3453-9. (Pubitemid 350160114)
39. Zlobec I, Lugli A, Baker K, et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 2007;212:260-8. (Pubitemid 47010060)
40. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9. (Pubitemid 27087710)
41. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60. (Pubitemid 38579481)
42. Ferreira CG, Epping M, Kruyt FA, et al. Apoptosis: target of cancer therapy. Clin Cancer Res 2002;8:2024-34. (Pubitemid 34753570)
43. Mannhold R, Fulda S, Carosati E. IAP antagonists: promising candidates for cancer therapy. Drug Discov Today 2010;15:210-19.
44. Cohen SJ, Engstrom PF, Lewis NL, et al. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am J Clin Oncol 2008;31:1-5.
45. Dineen SP, Roland CL, Greer R, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010;70:2852-61.
46. Lucas PW, Schmit JM, Peterson QP, et al. Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs. Invest New Drugs 2011;29:901-11.